Transfusion-dependent beta-thalassemia

Adult hemoglobin usually contains paired alpha- and beta-globin chains. When too little beta-globin is produced, developing red cells are damaged in the marrow and circulating cells may break down early. The result can be severe anemia.

“Transfusion-dependent” describes a clinical need for regular transfusions, rather than a single genetic variant. Severity and transfusion needs can change, and not all beta-thalassemia is transfusion dependent.

Most beta-thalassemia involves disease-causing variants in HBB. Common severe forms involve both copies of the gene; the amount of beta-globin produced and other inherited factors influence the course.

The condition occurs worldwide. Carrier testing and genetic counseling help explain family risks. Beta-thalassemia trait often causes mild or no anemia and should not be equated with transfusion-dependent disease.

Inadequately treated anemia can affect energy, growth and development. Increased marrow activity and an enlarged spleen can cause additional problems.

Regular transfusion controls anemia but adds iron that can accumulate in the heart, liver and endocrine organs. Iron-related complications can occur without obvious early symptoms, which is why monitoring and treatment remain necessary even when transfusions improve how someone feels.

Care centers on regular transfusion, iron chelation and monitoring for organ complications. The transfusion schedule and chelation medicine are tailored to the individual. Iron assessment uses blood tests and, where appropriate, imaging rather than a single ferritin measurement alone.

Luspatercept can reduce transfusion needs in some adults with beta-thalassemia. Mitapivat, marketed as Aqvesme, is FDA approved for anemia in adults with alpha- or beta-thalassemia. Its risks and monitoring requirements, including liver safety, need consideration; adult US approval does not establish access or suitability elsewhere.

Allogeneic transplantation uses a donor’s blood-forming cells and is an established potentially curative treatment. A suitable sibling or well-matched unrelated donor may be used. Outcomes depend on multiple factors, including existing iron-related organ injury; no single age cutoff predicts an individual result.

In the United States, Zynteglo adds a functional beta-globin gene to the patient’s own stem cells. Casgevy edits the patient’s cells to increase fetal hemoglobin. Both have specific indications and require conditioning chemotherapy. Neither requires a registry donor.

Regular treatment can mean scheduling transfusions, taking chelation and attending scans and specialist appointments over many years. Treatment choices should account for this practical burden alongside medical benefits and harms.

Before transplant or gene therapy, discussion includes fertility preservation, conditioning toxicity, infection, recovery and long-term monitoring. Donor transplantation also carries graft-versus-host disease risk. Iron overload may still need treatment after transfusions stop.

An unrelated donor can provide an established pathway when a suitable family donor is unavailable. Related donors need assessment of their hemoglobin status and overall suitability in addition to HLA matching.

A donor match is one part of a treatment decision. Some people continue transfusion-based care or receive other medicines; some pursue gene therapy using their own cells. Registry recruitment supports donor transplantation and should not be presented as a requirement for those autologous treatments.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?